Nicolet Advisory Services LLC Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Nicolet Advisory Services LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 10.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,351 shares of the company’s stock after buying an additional 323 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $386,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. International Assets Investment Management LLC grew its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC raised its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd purchased a new position in Novo Nordisk A/S in the third quarter worth $98,765,000. Marshall Wace LLP boosted its holdings in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $41,646,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.4 %

Shares of NVO opened at $105.06 on Friday. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The firm has a market capitalization of $471.46 billion, a price-to-earnings ratio of 34.00, a PEG ratio of 1.32 and a beta of 0.42. The firm’s 50-day moving average price is $115.48 and its 200-day moving average price is $128.80. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Wall Street Analysts Forecast Growth

NVO has been the topic of several analyst reports. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.